迪安诊断(300244) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 reached ¥4,876,446,577.16, representing a 37.48% increase year-over-year[5] - Net profit attributable to shareholders for the same period was ¥547,963,534.76, an 8.37% increase compared to the previous year[5] - The company reported a total revenue of ¥15,629,585,233.35 for the first nine months of 2022, a 67.37% increase year-over-year[14] - The diagnostic services business experienced significant growth, generating revenue of ¥9,875,000,000, a 117% increase year-over-year, excluding COVID-19 related income[14] - Total operating revenue for the third quarter reached ¥15,629,585,233.35, a significant increase from ¥9,338,149,453.42 in the previous year, representing a growth of approximately 67.5%[34] - The company's net profit attributable to shareholders increased to ¥5,832,062,228.80 from ¥3,488,040,081.22, marking a growth of around 67.0%[33] - The net profit for the current period is ¥2,867,805,689.73, a significant increase from ¥1,494,473,167.81 in the previous period, representing an increase of approximately 92%[36] - The total profit for the current period is ¥3,381,811,363.56, compared to ¥1,778,332,747.87 in the previous period, representing an increase of approximately 90%[36] Cash Flow and Liquidity - The company's cash flow from operating activities for the first nine months was ¥52,557,545.83, down 88.90% compared to the previous year[14] - Cash flow from operating activities increased to ¥12,086,152,872.35 from ¥8,766,159,447.67, marking a rise of approximately 38%[41] - The cash and cash equivalents at the end of the period decreased to ¥2,068,752,298.58 from ¥2,109,343,743.81, a decline of about 2%[43] - The company received cash from sales and services amounting to ¥11,891,901,448.05, an increase from ¥8,542,078,411.96, which is a growth of about 39%[41] - The net cash flow from investment activities was negative at -¥657,847,944.90, worsening from -¥304,536,662.65 in the previous period[41] Assets and Liabilities - The total assets at the end of the reporting period were ¥21,074,862,356.43, a 35.15% increase from the end of the previous year[5] - Total assets rose to ¥21,074,862,356.43, up from ¥15,594,035,702.21, which is an increase of approximately 35.0%[33] - Total liabilities increased to ¥10,737,924,012.45 from ¥8,118,148,058.94, representing a growth of about 32.4%[33] - The company reported a decrease in short-term borrowings to ¥1,540,345,726.24 from ¥2,509,595,453.39, indicating a reduction of approximately 38.5%[30] - The total equity attributable to shareholders reached ¥8,328,851,828.52, up from ¥5,841,975,826.13, reflecting an increase of about 42.5%[33] Research and Development - The company's R&D expenses for the first nine months amounted to ¥483,459,215.28, reflecting a 71.58% increase year-over-year[14] - Research and development expenses amounted to 483 million yuan, representing a 72% increase compared to the same period last year[15] - Research and development expenses were ¥483,459,215.28, compared to ¥281,760,860.48 in the same period last year, reflecting an increase of approximately 71.5%[34] Shareholder Information - The first phase of the employee stock ownership plan acquired 714,200 shares through secondary market transactions in January 2022[22] - The first batch of the 2020 restricted stock incentive plan vested for 455 individuals, with a total of 3.4548 million shares at a grant price of 24.585 yuan per share[22] - The actual controller, Chen Haibin, had a cumulative pledge of shares amounting to 9.64% of the total share capital[23] - The top ten shareholders held a combined 66.88% of the company's shares[18] Future Projections - The company plans to achieve a revenue target of ¥15.63 billion in the third year of its five-year strategy, with a projected net profit of ¥2.43 billion[14]